Lonza, Vineti team up to address risks in the ‘vein-to-vein’ supply chain

By Maggie Lynch

- Last updated on GMT

(Image: Getty/Busakorn Pangparnit)
(Image: Getty/Busakorn Pangparnit)

Related tags Lonza Supply chain Gene cell and gene therapy

Lonza enters a partnership with Vineti to advance its ‘vein-to-vein’ delivery network, creating an end-to-end ordering and manufacturing process in support of cell and gene therapy development.

Lonza entered the non-exclusive business collaboration in an aim to remove the current roadblocks developers of personalized therapeutics often face in the supply chain as drug products prepare for commercial launch, according to the company.

Alberto Santagostino, head of cell and gene technologies at Lonza, told us, “The cell and gene therapy industry is at a global inflection point, with a need to mature and industrialize to grow and deliver on its potential.”

“The Vineti-Lonza partnership is in pursuit of an end-to-end ordering and manufacturing process that will bring optimization and standardization to cell and gene therapy manufacturing, allowing the industry to grow and scale as efficiently and simply as possible,”​ he explained.

The collaboration will see the integration of the Vineti Personalized Therapy Management Platform with the Lonza Orchestrate capacity management system.

“Vineti’s proven software solution connects and orchestrates the ecosystem responsible for bringing a cell therapy, gene therapy, or personalized cancer vaccine to the patient,”​ said Santagostino.

Per the partnership, Lonza will be able to offer integrated logistics, scheduling, distribution, chain or condition, chain of custody, chain of identity services, along with its proprietary solutions. These offerings come as Lonza gains access to the Vienti supply chain orchestration (SCO) platform through the partnership.

Santagostino also said that this collaboration is part of Lonza’s wider goal to create a network of partnerships and capabilities that enable a ‘vein-to-vein’ delivery of cell and gene therapies.

The solution developed from the partnership will also be working to provide this integrated system worldwide using Lonza’s manufacturing and Vineti’s network of medical centers.

“Overall, the cell and gene therapy supply chain is complex – involving patients, health care providers, sponsors, pharma companies, white glove couriers, and CDMOs. It has a lot of moving parts and carries a lot of inherent risks,”​ explained Santagostino.

He stated, “The Lonza-Vineti partnership is designed to address those risks and complexities.”

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more